Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.

Slides:



Advertisements
Similar presentations
2014 “Towards an HIV Cure” symposium Melbourne Genetically Characterizing the Role of Cell Proliferation in Maintaining Persistent HIV during Effective.
Advertisements

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):
CXCR4-tropism and the preferential establishment of an HIV-reservoir in naïve CD4+ T-cells among HIV-infected Ugandan children Theodore Ruel 1, Jane Achan.
Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.
High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection Abstract.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.
Measuring the latent HIV Reservoir
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Korde N et al. Proc ASH 2014;Abstract 2105.
Biology and natural history of the virus
HIV, CD4, and More Karen Hutcherson Jenn Mann Elizabeth McCauley Michael Powers Courtney Wilson.
DEVELOPMENT OF THE TOOLS FOR PCR-DETECTION OF HEPATITIS A AND C VIRUSES IN INTRAHOSPITAL VIRAL CONTAMINATION RESEARCH. 1 D. I. Ivanovsky Virology Institute,
Plate 87 Acquired Immune Deficiency Syndrome (AIDS)
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,
HIV Cellular Pathogenesis III
Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens Giron, LB; Tenore, S; Gabriel, R; Janini,
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
1 Modelling the interactions between HIV and the immune system in hmans R. Ouifki and D. Mbabazi 10/21/2015AIMS.
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
1 Resistance and Tropism - Maraviroc Lisa K. Naeger, Ph.D. Division of Antiviral Products Food and Drug Administration April 24, 2007 FDA Antiviral Advisory.
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Challenges to replacing CD4 testing with viroloigical monitoring Andrew Hill, Pharmacology Research Laboratories, University of Liverpool, UK World AIDS.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Persistent HIV-1 infection in duodenal mucosa and memory CD8+ T cell differentiation Liliana Belmonte 1 PhD; Alberto Zalar 2 MD; Patricia Baré 1 PhD; Noel.
Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.
HIV-1 infection decreases CD127 and PD1 expression on duodenal CD8+T cells Liliana Belmonte, PhD Academia Nacional de Medicina Buenos Aires, Argentina.
HIV pathogenesis The course of HIV infection 1. Acute Phase 2. Intermediate (asymptomatic) phase -viral load stabilizes at a “set point”. 3. Late (symptomatic)
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
Immune reconstitution Anjie Zhen, PhD
2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.
Date of download: 5/28/2016 From: Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases Ann.
Date of download: 6/3/2016 From: Report of the NIH Panel To Define Principles of Therapy of HIV Infection* Ann Intern Med. 1998;128(12_Part_2):
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Background  HIV-1 infection persists in reservoirs and leads to progressive depletion of CD4+ T-cells even in subjects with slow disease progression 
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: HIV-1 Drug Resistance Profiles in Children and Adults.
T-CELL MEMORY Central Effector.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Expression Analysis of α4 integrin and related genetic polymorphisms in HIV acquisition and disease progression OF infected individuals Livia R. GóeS 1,
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
Emory University School of Medicine Department of Medicine
State of HIV Cure Research
No Evidence Of Ongoing Replication In Tissue Compartments During cART
HIV Cure: Current Status and Future Perspectives
Feedback meeting September 2017
EBV Persistence in Memory B Cells In Vivo
HEATHER Feedback Meeting
V. Bordoni, M. Bibas, I. Abbate, D. Viola, G. Rozera, C. Agrati, A
Human Health and Disease
Blood T-cell receptor diversity decreases during the course of HIV infection, but the potential for a diverse repertoire persists by Paul D. Baum, Jennifer.
Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy  Yuka Igarashi, Toru Uchiyama, Tomoko Minegishi, Sirirat.
Antibodies and B Cell Memory in Viral Immunity
Volume 12, Issue 1, Pages (July 2005)
What Integration Sites Tell Us about HIV Persistence
Volume 12, Issue 4, Pages (April 2000)
Volume 21, Issue 3, Pages (October 2017)
The Expression Pattern of Epstein-Barr Virus Latent Genes In Vivo Is Dependent upon the Differentiation Stage of the Infected B Cell  Gregory J Babcock,
EBV Persistence in Memory B Cells In Vivo
Mayibongwe L. Mzingwane, PhD Department of Pathology
Presentation transcript:

Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated lymphoid tissue from patients on long-term suppressive therapy Lina Josefsson Karolinska Institutet, Solna, Sweden “Towards an HIV Cure” Pre-Conference Symposium 20 & 21 July 2012

Background Persistent HIV can still be detected in plasma and cellular reservoirs even after several years of suppressive antiretroviral therapy Identifying the source and dynamics of persistent HIV in patients on suppressive therapy is an important step towards HIV eradication

Objectives of the study Use single-genome and single-proviral sequencing assays, to investigate the: – Source of persistent HIV-1 What cells are HIV reservoirs during suppressive therapy? – Dynamics of persistent HIV-1 Does low-level viral replication maintain HIV during suppressive therapy? 8 patients on suppressive antiretroviral therapy (4-12 years) – 5 initiating therapy during acute/early infection (< 6months) – 3 initiating therapy during chronic infection (> 1.5year) Peripheral blood (PB) Bone Marrow (BM) Gut Associated Lymphoid Tissue (GALT) Lymph Node Tissue (LN)

Layout of the study 19 oktober 2015Lina Josefsson4 Initiation of cART Plasma 1) Chronic: 1-3years Plasma 2) Chronic: 1-6 months Acute/early: 0-12 days Cells: Progenitor (CD34+ Lin-) Late progenitor (CD34-, Lin-) (CD34+, Lin-) Lymphoid cells (Lin+ CD4+) Naïve (CD45RO-CD27+) Central Memory (CD45RO+CD27+) Effector Memory (CD45RO+CD27-) Myeloid (CD3- CD4lo ) 5 patients treated during acute/early infection 3 patients treated during chronic infection 1.Investigate the source of persistent HIV-1 - Characterization of HIV-1 in infected cells after long-term suppressive cART 2.Investigate the dynamics of persistent HIV-1 - Compare pre-therapy HIV-1 populations to HIV-1 populations after long-term suppressive cART Treatment naive HIV-1 < 75 copies/ml 4 – 12 years LNPB GALT BM P6, protease, RT gag-pro-pol

Higher frequency of infection in cells isolated from patients treated during chronic infection compared to patients treated during acute/early infection Peripheral blood a p <0.05 * One cannot rule out the possibility of low but nonzero infection rates in cases where estimates were zero, as shown by the upper confidence bounds. ** Numbers in parenthesis denotes the frequency of infection found in myeloid lysate with T-cell receptors present. *** For calculation of geometric means, estimated infection rates of zero were replaced with 1/(number of cells tested) 0.007% 0.06% X9 0.01% 0.03% X3 0.01% 0.13% X13 a % 0.01% X24 a

Gut Associated Lymphoid Tissue Higher frequency of infection in cells isolated from patients treated during chronic infection compared to patients treated during acute/early infection * One cannot rule out the possibility of low but nonzero infection rates in cases where estimates were zero, as shown by the upper confidence bounds. ** Numbers in parenthesis denotes the frequency of infection found in myeloid lysate with T-cell receptors present. *** For calculation of geometric means, estimated infection rates of zero were replaced with 1/(number of cells tested) 0.009% 0.03% 0.02% 0.15% 0.07% 0.08% X4X6 a X1.2 a p <0.05

No infected progenitor cells isolated from bone marrow * One cannot rule out the possibility of low but nonzero infection rates in cases where estimates were zero, as shown by the upper confidence bounds. Bone marrow a p < 0.05 Josefsson et al, JID 2012 X13 a

Phylogenetically indistinguishable HIV-1 sequences from plasma collected before initiation of cART and cells isolated after several years of suppressive therapy Patient 4 Treated during early infection > 6 years on therapy Peripheral blood – Central memory Peripheral blood – Effector memory On-therapy Peripheral blood – All memory Peripheral blood – Naive Pre-therapy Plasma GUT – Effector memory Lymph node – Effector memory Lymph node– Transitional memory Bone marrow – Lin+CD

Phylogenetically indistinguishable HIV-1 sequences from plasma collected before initiation of cART and cells isolated after several years of suppressive therapy Patient 8 Treated during chronic infection >8 years of therapy Peripheral blood – Central memory Peripheral blood – Effector memory On-therapy Peripheral blood- All memory Peripheral blood – Naive Pre-therapy Plasma GUT – Effector memory GUT – Central memory GUT– Naive Lymph node– Effector memory Lymph node – Central memory Lymph node– Transitional memory Lymph node– Naive Bone marrow – Lin+CD4+ Bone marrow – Lin-CD

No clear detection of viral evolution between sequences isolated from pre-therapy plasma and sequences isolated from peripheral blood or GALT collected after 4-12 years of suppressive cART 3 different approaches to investigate the amount of viral evolution between sequences from plasma before the initiation of therapy and sequences from cells after 4-12 years of suppressive cART Genetic distance Correlation of genetic divergence and time Evolutionary rate analysis Genetic distance between: 1. Sequences from pre-therapy and on-therapy 2.Sequences from pre-therapy 3.Sequneces from on-therapy Correlation of genetic divergence and time between: 1. Pre-therapy and on-therapy 2.Pre-thearpy (1) and pre-therapy(2) for patients treated during chronic infection Nucleotide substitutions per site per year between: 1. Pre-therapy and on-therapy 2. Pre-therapy (1) and pre-therapy(2) for patients treated during chronic infection Comparison of genetic distance between sequences from the same time point differ no more than the comparision of sequences between PT and OT indicating no evolutionary change during suppressive therapy No correlation between genetic divergence and time between pre-therapy and on-therapy sequences indicating no evolutionary change during suppressive thereapy. Correletion between pre-therapy (1) and pre-thearpy (2). Nucleotide substitutions per site per year: 1. Patients treated during early infection: mean = 10e-5 2. Patients treated during chronic infection: mean = 10e-4 3. Pre-therapy sequences from patients treated during chronic infection mean = 10e-3 Genetic distance Genetic distance between: 1. Sequences from pre-therapy and on-therapy 2.Sequences from pre-therapy 3.Sequneces from on-therapy Comparison of genetic distance between sequences from the same time point differ no more than the comparison of sequences between PT and OT indicating no evolutionary change during suppressive therapy Correlation of genetic divergence and time Correlation of genetic divergence and time between: 1. Pre-therapy and on-therapy 2.Pre-thearpy (1) and pre-therapy(2) for patients treated during chronic infection No correlation between genetic divergence and time between pre-therapy and on- therapy sequences indicating no evolutionary change during suppressive therapy. Correlation between pre-therapy (1) and pre-therapy (2). R 2 = – Evolutionary rate analysis Nucleotide substitutions per site per year between: 1. Pre-therapy and on-therapy 2. Pre-therapy (1) and pre-therapy (2) for patients treated during chronic infection Nucleotide substitutions per site per year: 1. Patients treated during early infection: mean = 10e-5 2. Patients treated during chronic infection: mean = 10e-4 3. Pre-therapy sequences from patients treated during chronic infection mean = 10e-3 Nucleotide substitutions per site/year: Early infection: 10e-5 Chronic infection: 10e-4 Pre-therapy: 10e-3

Conclusions T-cells were found to be infected in all patients after long-term suppressive therapy. No progenitor cells were found to be infected and myeloid cell samples contained T-cell receptors Early initiation of effective therapy results in lower reservoir size No clear evidence for evolution could be detected in patients treated during early and chronic infection The lack of clear evidence for HIV-1 genetic evolution in the HIV-1 infected CD4+ T-cell populations after years of therapy argues against virus replication as a major cause of persistence in these cell populations. – The role of replication in other tissues and cell types however remains to be defined.

Acknowledgements We acknowledge with gratitude the participation of all the patients in this study University of California, San Francisco F. Hecht E. Sinclair P. Bacchetti P. Lewis P. Hunt M.Somsouk H. Hantano S. Deeks L. Epling M. Kilian T. Ho A. Tan J. Custer L. Loeb R. Hoh L. Poole Karolinska Institutet The Swedish Institute for Communicable Disease Control S. Palmer S. Eriksson V. Dahl M. Mild J. Albert Rega Institute, Belgium N. Faria P. Lemey SAIC/NCI W. Shao VRC/NIAID D. Douek W. Wylie

Patient information Patient Viral Load Pre Therapy (RNA copies/ml) Viral Load On Therapy* (RNA copies/ml) CD4+ T-cell Count Pre Therapy (cells/ul) CD4+ T-cell Count On Therapy (cells/ul) Lenght of infection (years) Time on therapy (years) Treated during acute/early infection < < < < < Treated during chronic infection < < < * Viral RNA levels at the time of the study

Results – genetic distance Patient Genetic distance (%) (Pre-therapy sequences and on- therapy sequences) Genetic distance (%) (Pre-therapy sequences) Genetic distance (%) (On-therapy sequneces) Initiated therapy during acute/early infection Initiated therapy during chronic infection 6*0.87N/A *5.51N/A *1.43N/A * Pre-therapy samples collected 1-3 years apart

Results – regression analysis Patient Correlation of genetic divergence and time R2R2 Initiated therapy during acute/early infection 12.78E E E E E-02 Initiated therapy during chronic infection 6* E-03 7* * * Pre-therapy samples collected 1-3 years apart

Results – evolutionary rate analysis Treated during early infection Treated during chronic infection

0.01

18 Sort by cell type using FACS Single-proviral Sequencing PCR Amplify each HIV genome from the lysate and sequence P6, protease, RT gag-pro-pol Calculate genetic relationship to plasma sequences from sample taken before and after long-term therapy Align sequences Patient Cells from peripheral blood, bone marrow, lymphoid tissue and GUT Lyse sorted cells DNA endpoint dilution Cell lysate Positive PCR reactions Josefsson et. al. JID 2012

19 oktober 2015Namn Efternamn19 Multiple Alignment File cDNA endpoint dilution Agarose gel P6, protease, RT gag-pro-pol Sequence individual genomes Palmer et. al. J Clin Micro 2005 Kearney et. al. J Virol 2008 Single-Genome Sequencing of Plasma Samples